OleanderPhoenix raises >$3,000,000 from angel investors. Posted on July 2010June 2022 by Carlos Torres 06 Jul Publication: Human tumor cell sensitivity to oleandrin is dependent on relative expression of Na+, K+ -ATPase subunits. Phoenix Biotechnology executes a fifth amendment to its Sponsored Research Agreement with M. D. Anderson Cancer Center.
